Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid
malignancies, however, its use for solid malignancies remains a challenge. The putative …

Introduction In the last decade, two new radionuclide-based therapies, 223Radichloride and
radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been …

Purpose: Radiopharmaceutical therapy is changing the standard of care in prostate cancer
and other malignancies. We previously reported high CD46 expression in prostate cancer …

Radiopharmaceuticals play a vital role in cancer therapy. The carrier of
radiopharmaceuticals can precisely locate and guide radionuclides to the target, where …

Abstract Lutetium-177 [T½= 6.76 d; E β (max)= 0.497 MeV; maximum tissue range~ 2.5 mm;
208 keV γ-ray] is one of the most important theranostic radioisotope used for the …

Prostate cancer remains a major cause of mortality and morbidity, affecting millions of men,
with a large percentage expected to develop the disease as they reach advanced ages …

Here we describe an anti–prostate-specific membrane antigen (PSMA) minibody (IAB2MA)
conjugated to an octadentate, macrocyclic chelator based on four 1-hydroxypyridin-2-one …

Background Programmed cell death 1 ligand 1 (PD-L1) is overexpressed in many tumors.
The radionuclide-labeled anti-PD-L1 monoclonal antibody can be used for imaging and …

Radiotheranostics is a rapidly growing approach in personalized medicine, merging
diagnostic imaging and targeted radiotherapy to allow for the precise detection and …

Introduction In recent years, prostate specific membrane antigen (PSMA) has been gaining a
crucial role for prostate cancer (PC) management, representing an ideal platform to combine …